Surrogate endpoints for survival in KEYNOTE-585: neoadjuvant/adjuvant pembrolizumab plus chemotherapy versus placebo plus chemotherapy for gastric or gastroesophageal junction adenocarcinoma
These findings suggest a potential association between pCR, mPR, or pDS and survival in patients with locally advanced gastric or GEJ adenocarcinoma, although further validation is needed.
Authors
- C.-J. Yen
- L.S. Wyrwicz
- C.-S. Shih
- F. Pietrantonio
- M. Moehler
- R. Krishnan
- W.P. Yong
- J.-P. Metges
- S. Lonardi
- S.Y. Rha
- A. Spallanzani
- S.-E. Al-Batran
- S. Pelles-Avraham
- E W Jensen
- M. Garrido
- K. Shitara
- Y.-J. Bang
- P. Yañez
- Y.-K. Park
- T. Oshima
Institutions
- Goethe University Frankfurt (DE)
- Universidad de La Frontera (CL)
- University of Modena and Reggio Emilia (IT)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Seoul National University (KR)
- Yonsei University (KR)
- Johannes Gutenberg University Mainz (DE)
- Tel Aviv Sourasky Medical Center (IL)
- Kanagawa Prefectural Hospital Organization (JP)
- National University Cancer Institute, Singapore (SG)
- Istituto Oncologico Veneto (IT)
- University Hospital Frankfurt (DE)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Krankenhaus Nordwest (DE)
- National Cancer Center Hospital East (JP)
- Chonnam National University Hwasun Hospital (KR)
- The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Kanagawa Cancer Center
- National Cheng Kung University (TW)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106090
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00